Prescient is an evidence-based decision-support partner to the pharmaceutical and biotech industries whose mission is to optimally shape new product, brand and mature product planning strategies.

Our diverse yet integrated skillsets and methodologies ensure our clients’ key decisions are objectively assessed from both a clinical and commercial perspective, resulting in differentiated products and offerings.


Shaping Decisions Driving Value

Our People

Prescient’s team consists of highly experienced executives who share our core values of thinking collaboratively, creatively and constructively. We effectively integrate different skills and perspectives into a single client-engagement team.

Our Approach

The format and scope of our engagements are customized to meet our clients’ needs and our ‘best-in-front’ team philosophy ensures access to the necessary levels of expertise and thinking.

Our Clients

We engage directly with a number of functions supporting new product, brand and mature product planning activities; to view a full list of these, please click the
link below.

Latest News

Pfizer awarded grant to evaluate vaccine to protect newborns against group B Streptococcus infection

FDA approves Roche's cancer immunotherapy TECENTRIQ (atezolizumab) for people with a specific t …

Anti-inflammatory drugs could help treat symptoms of depression

Bristol-Myers Squibb Foundation joins White House Cancer Moonshot

FDA awards 21 grants to stimulate product development for rare diseases

Merck launches Biosimilars Clarified, a new online educational resource about biosimilar medicines f …

Depriving deadly brain tumors of cholesterol may be their Achilles' heel

MS drug may reverse some physical disability

New findings challenge current view of how pancreatic cancer develops

Daiichi Sankyo announces TaNeDS Europe 2017 collaborative drug discovery programme

Discovery and gene therapy treatment of a novel heart failure mechanism

Dangerous drug interactions uncovered with data science

Merck announces recipients of third annual €1 million 'Grant for Oncology Innovation' awar …

First human clinical trial for nicotinamide riboside

AstraZeneca enters agreement with Cilag GmbH International to divest rights to Rhinocort Aqua outsid …

PTC, partner Roche to kick-start PhII SMA study; SMA Type 1 test on the horizon

NeuroVive ends standoff with Arbutus, regains hep B drug

Alkermes third time lucky with ALKS 5461, but doubts linger

Ex-Moderna CSO resurfaces at PureTech after abrupt departure

Roche highlights I/O combos, as it drops solo development of vanucizumab

Gilead drops PAH, DKD tests after PhII failure; highlights positive noises for NASH

UPDATED: J&J backs neuro startup BlackThorn in $40M Series A

Small cap Rigel drops on PhIII failure for lead fostamatinib

FDA panel gives the nod to Allergan’s night-time urinary drug

FDA's new drugs director slams Sarepta, says biotech’s approval ‘NOT a good model’

Eli Lilly gains FDA approval for new sarcoma med Lartruvo

AbbVie rejects Ablynx RA drug on cusp of PhIII

Novartis invests, partners with Y Combinator grad in lysosomal storage disorders

Merck gets first-line NSCLC guideline as Bristol, Roche denied

Novartis partners with tiny microcap Cerulean as it nabs $20M

AusBiotech members unite in response to R&D Tax Incentive review

FDA accepts Teva’s resubmission of SD-809 NDA

In a change of heart, NICE recommends Opdivo for advanced renal cell cancer

Gilead reports positive Phase III results of three-antiviral fixed-dose hepatitis C candidate

Ablynx outlines next steps, as AbbVie pulls out of vobarilizumab option

Debiopharm collaborates with Merck and Pfizer on cancer immunotherapy

Cerulean rockets on news of a collaboration with Novartis

Roche delivers 3rd-qtr sales growth of 4.5%, but misses forecasts

Accelerated US approval for Lilly’s Lartruvo for advanced soft tissue sarcoma

TxCell teams up with UBC on human CAR-Treg cells in a preclinical model of transplantation

German prescription drug price rule quashed by EU court

Colombian pharma market to see strong market growth: report

Celgene gets positive NICE opinion for Otezla in plaque psoriasis

NICE issues draft guidance backing Galafold for Fabry disease

FDA gives thumbs up for Roche’s Tecentriq for some patients with NSCLC

Medical News Today: New guidelines for kids' media use help families balance digital, real life

Medical News Today: Schizophrenia risk increased with alcohol, drug abuse

Medical News Today: How to Get Rid of Red Eyes: Home Remedies and Health Tips

Medical News Today: 'Marijuana receptor' uncovered in new study

Medical News Today: Childhood cancer survivors with poor diet at risk of chronic illness

Medical News Today: Cancer hijacks common immune cell weapon to promote spread

Medical News Today: Basal Ganglia Stroke: Symptoms, Causes, and Treatment

Medical News Today: Eight superfoods you've never heard of but need to know

Medical News Today: Schizophrenia secrets found hidden in the folds of DNA

Medical News Today: Regular exercise may safeguard against memory loss

Medical News Today: Stress hormone in hair could predict IVF outcomes

Medical News Today: Football-related concussion: A call for action

Medical News Today: Bipolar Disorder and Alcohol: What's the Connection?

Medical News Today: Hot flashes in menopause may have genetic links

Medical News Today: PCOS: Red wine compound remedies abnormal hormone levels

NICE u-turn backs Opdivo for kidney cancer

Gov’t announces cuts to community pharmacy budget

Merck, Pfizer link with Debiopharm to test immunotherapy combo

Alkermes boosted by trial success for antidepressant

New surgeries and upgraded clinics for GP practices

Psoriasis patients to get NHS access to Otezla

Lilly’s Lartruvo bags US nod for soft tissue sarcoma

FDA panel backs Allergan’s night-time urination nasal spray

Genentech’s Tecentriq wins US nod for lung cancer

FDA accepts resubmission of AZ’ potassium-binder

EU green light for Shire’s pancreatic cancer drug Onivyde

NICE backs new therapy for Fabry disease

NHS cuts annual spend on agency staff by £600m

FDA rejects PTC’s appeal over failed Translarna filing

NHS England launches £400K digital mental health fund

More News